×
About 64,266 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  30,383 results

Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine se...
https://doi.org/10.1186/s12885-020-07722-3 10.1038/nrdp.2016.22 10.6004/jnccn.2017.0131 10.1245/s10434-009-0409-5 10.1002/cncr.24410 10.1001/jama.2010.1275 10.1016/S0140-6736(16)30583-9 10.1053/j.seminoncol.2007.01.006 10.1073/pnas.93.1.136 10.1309/F1B64CL7H8VJKEAF 10.1158/1535-7163.MCT-07-0483 10.1186/s12943-017-0633-8 10.1038/bjc.2012.235 10.3892/ol.2015.2969 10.1097/MPA.0b013e318221bed8 10.4291/wjgp.v7.i2.218 10.1007/s00535-013-0773-6 10.3892/ijo.2012.1662 10.1158/2159-8290.CD-15-0583 10.1007/s10637-014-0196-0 10.18632/oncotarget.26117 10.18632/oncotarget.23684 10.1128/MCB.20.8.2902-2906.2000 10.2174/1871520611313020014 10.1016/S0016-5085(03)01064-3 10.1038/sj.onc.1206966 10.1016/S0304-3835(03)00482-8 10.1053/gast.2002.37075 10.1158/1541-7786.MCR-08-0095 10.1158/1541-7786.MCR-07-0254 10.1042/BJ20082196 10.1136/jcp.2004.025338 10.1186/1756-9966-31-84 10.1038/35102167 10.1038/nrc1590 10.1126/science.1171837 10.1007/s00018-010-0338-2 10.1371/journal.pone.0013943 10.1053/j.gastro.2009.05.053 10.1371/journal.pone.0002428 10.1186/scrt166 10.1038/sj.cdd.4402283 10.1016/j.ccr.2004.05.032 10.1038/nrc3205 10.1373/clinchem.2012.184655 10.1016/j.bbrc.2017.01.111 10.1111/j.1432-0436.2008.00295.x 10.1016/j.lungcan.2009.07.016
BMC Cancer; Matsuzawa F, Kamachi H et. al.

Feb 27th, 2021 - Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently ...

Advances in the Management of Cancer-Associated Thrombosis.
https://doi.org/10.1055/s-0041-1722863
Seminars in Thrombosis and Hemostasis; Dhami SPS, Patmore S et. al.

Feb 26th, 2021 - The association between cancer and venous thromboembolism (VTE) has been established for more than 150 years. Nevertheless, cancer-associated thrombosis still remains a major clinical challenge and is associated with significant morbidity and mort...

A case-control study of occupational risk factors for pancreatic cancer in poultry plan...
https://doi.org/10.1093/pubmed/fdab008
Journal of Public Health (Oxford, England); Faramawi MF, Abouelenein S et. al.

Feb 26th, 2021 - Poultry plant workers are exposed to chemical carcinogens and oncogenic viruses in their work environment. Our objective was to identify jobs and workplaces related to poultries that could increase the pancreatic cancer risk. We conducted a case-c...

PGE2 released by pancreatic cancer cells undergoing ER stress transfers the stress to D...
https://doi.org/10.1158/1535-7163.MCT-20-0699
Molecular Cancer Therapeutics; Cirone M, Gilardini Montani MS et. al.

Feb 26th, 2021 - This study shows that pancreatic cancer cells undergoing cell death by Valproic Acid (VPA) treatment activated DCs more efficiently than those treated with Trichostatin A (TSA), as demonstrated by CD86 and CD80 surface expression. Surprisingly tho...

Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic ...
https://doi.org/10.1177/0003134821998671
The American Surgeon; Okano K, Suto H et. al.

Feb 25th, 2021 - Although the efficacy of neoadjuvant therapies for pancreatic cancer (PDAC) is reported in recent years, ideal neoadjuvant treatment for patients with potentially resectable (R) PDAC remains uncertain. We conducted the retrospective study about th...

see more →

Guidelines  89 results

Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077959
Pancreas Okusaka T, Nakamura M et. al.

Mar 6th, 2020 - Clinical Practice Guidelines for Pancreatic Cancer were first published in 2006 by the Japan Pancreas Society, and they were revised in 2009, 2013, and 2016. In July 2019, the Clinical Practice Guidelines for Pancreatic Cancer 2019 were newly revi...

Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practic...
https://doi.org/10.1016/j.prro.2019.06.016
Practical Radiation Oncology; Palta M, Godfrey D et. al.

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recomm...
https://doi.org/10.1001/jama.2019.10232
JAMA , Owens DK et. al.

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Screening for Pancreatic Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2740726
JAMA

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  32,283 results

Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine se...
https://doi.org/10.1186/s12885-020-07722-3 10.1038/nrdp.2016.22 10.6004/jnccn.2017.0131 10.1245/s10434-009-0409-5 10.1002/cncr.24410 10.1001/jama.2010.1275 10.1016/S0140-6736(16)30583-9 10.1053/j.seminoncol.2007.01.006 10.1073/pnas.93.1.136 10.1309/F1B64CL7H8VJKEAF 10.1158/1535-7163.MCT-07-0483 10.1186/s12943-017-0633-8 10.1038/bjc.2012.235 10.3892/ol.2015.2969 10.1097/MPA.0b013e318221bed8 10.4291/wjgp.v7.i2.218 10.1007/s00535-013-0773-6 10.3892/ijo.2012.1662 10.1158/2159-8290.CD-15-0583 10.1007/s10637-014-0196-0 10.18632/oncotarget.26117 10.18632/oncotarget.23684 10.1128/MCB.20.8.2902-2906.2000 10.2174/1871520611313020014 10.1016/S0016-5085(03)01064-3 10.1038/sj.onc.1206966 10.1016/S0304-3835(03)00482-8 10.1053/gast.2002.37075 10.1158/1541-7786.MCR-08-0095 10.1158/1541-7786.MCR-07-0254 10.1042/BJ20082196 10.1136/jcp.2004.025338 10.1186/1756-9966-31-84 10.1038/35102167 10.1038/nrc1590 10.1126/science.1171837 10.1007/s00018-010-0338-2 10.1371/journal.pone.0013943 10.1053/j.gastro.2009.05.053 10.1371/journal.pone.0002428 10.1186/scrt166 10.1038/sj.cdd.4402283 10.1016/j.ccr.2004.05.032 10.1038/nrc3205 10.1373/clinchem.2012.184655 10.1016/j.bbrc.2017.01.111 10.1111/j.1432-0436.2008.00295.x 10.1016/j.lungcan.2009.07.016
BMC Cancer; Matsuzawa F, Kamachi H et. al.

Feb 27th, 2021 - Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently ...

Advances in the Management of Cancer-Associated Thrombosis.
https://doi.org/10.1055/s-0041-1722863
Seminars in Thrombosis and Hemostasis; Dhami SPS, Patmore S et. al.

Feb 26th, 2021 - The association between cancer and venous thromboembolism (VTE) has been established for more than 150 years. Nevertheless, cancer-associated thrombosis still remains a major clinical challenge and is associated with significant morbidity and mort...

A case-control study of occupational risk factors for pancreatic cancer in poultry plan...
https://doi.org/10.1093/pubmed/fdab008
Journal of Public Health (Oxford, England); Faramawi MF, Abouelenein S et. al.

Feb 26th, 2021 - Poultry plant workers are exposed to chemical carcinogens and oncogenic viruses in their work environment. Our objective was to identify jobs and workplaces related to poultries that could increase the pancreatic cancer risk. We conducted a case-c...

PGE2 released by pancreatic cancer cells undergoing ER stress transfers the stress to D...
https://doi.org/10.1158/1535-7163.MCT-20-0699
Molecular Cancer Therapeutics; Cirone M, Gilardini Montani MS et. al.

Feb 26th, 2021 - This study shows that pancreatic cancer cells undergoing cell death by Valproic Acid (VPA) treatment activated DCs more efficiently than those treated with Trichostatin A (TSA), as demonstrated by CD86 and CD80 surface expression. Surprisingly tho...

Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic ...
https://doi.org/10.1177/0003134821998671
The American Surgeon; Okano K, Suto H et. al.

Feb 25th, 2021 - Although the efficacy of neoadjuvant therapies for pancreatic cancer (PDAC) is reported in recent years, ideal neoadjuvant treatment for patients with potentially resectable (R) PDAC remains uncertain. We conducted the retrospective study about th...

see more →

News  1,327 results

Cancer Death Rates Continue to Fall in Europe, Except For...
https://www.medscape.com/viewarticle/946288

Feb 22nd, 2021 - Cancer death rates overall continue to fall among both men and women in Europe, with the notable exception of pancreatic cancer in both sexes and lung cancer among women living in the European Union, notes an update report. "Among the major cancer...

High Cost of Pancreatic Enzymes a Barrier for Patients With Cancer
https://www.medscape.com/viewarticle/944683

Jan 25th, 2021 - Pancreatic enzyme replacement therapy (PERT) is often an essential component of the treatment regimen for patients with pancreatic cancer, but it can be very pricey. "Out-of-pocket costs for a 30-day supply of enzymes for Medicare beneficiaries ca...

New Standard for Borderline Resectable Pancreatic Cancer
https://www.medscape.com/viewarticle/944381

Jan 19th, 2021 - Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is controversial. New results suggest that the reference reg...

NHS England Starts Pilot Trial of Blood Test for Many Cancers
https://www.medscape.com/viewarticle/942024

Dec 3rd, 2020 - A simple blood test, claimed to detect more than 50 types of cancer, will be used in a pilot trial by National Health Service (NHS) England in a bid to increase rates of early-stage diagnosis, in particular for cancers that are currently difficult...

Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed 
https://www.staging.medscape.com/viewarticle/941278

Nov 18th, 2020 - The PARP inhibitor olaparib (Lynparza) has been shown to delay progression  in patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations, and is now approved for this indication. A new study suggests that this approach can be cost-e...

see more →

Patient Education  93 results see all →